A recent study indicated that patient-reported outcome measures (PROMs) should be used more frequently in outpatient settings to help improve shared decision-making conversations between patients and providers.
For psoriatic arthritis, enthesitis is a key trait that echographic ultrasounds is supported for the diagnosis of pre-clinical signs of enthesitis in asymptomatic patients at high risk for advanced forms.
Aiming to evaluate the effect of withdrawing ixekizumab in patients with psoriatic arthritis who had achieved minimal disease activity after open-label ixekizumab treatment, a study found continued IXE treatment is superior in maintaining low disease activity.
A study published in Clinical Rheumatology evaluated changes in health-related quality of life (HRQoL) and productivity following treatment with intravenous (IV) golimumab in patients with psoriatic arthritis (PsA), finding golimumab resulted in early and sustained improvements.
An increased risk of TB and LTBI reactivation may be due to methotrexate, cyclosporine, and tumor necrosis factor inhibitors, although there are limited data on the risks of TB with use of newer biologics.
Published in International Journal of Rheumatic Diseases, a study evaluated the relationship of fibromyalgia with enthesopathy, sleep, fatigue, and quality of life in patients with psoriatic arthritis (PsA).
A study published in Annals of the Rheumatic Diseases was conducted to compare the efficacy and safety of brodalumab, an interleukin (IL) 17 receptor subunit A inhibitor, with placebo, in patients with psoriatic arthritis (PsA).